Olmesartamedoxomil/Hydrochloorthiazide Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil/hydrochlorothiazide is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: helps lower systolic and diastolic blood pressure when used alone or with other antihypertensives.
• Heart failure prevention: contributes to reduced risk of cardiovascular events in patients with hypertension.
• Chronic kidney disease: assists  as  part of  blood‑pressure control  in  patients  with  early  renal  impairment.

• Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, promoting diuresis and further lowering blood volume and pressure. Together they provide complementary antihypertensive effects through vascular relaxation and fluid reduction.

Common Side Effects

• Dizziness  :  light‑headed  feeling  often  transient.
• Headache  :  mild  to  moderate  head  pain.
• Fatigue  :  generalized  tiredness.
• Increased urination  :  more frequent  urine  output.
• Electrolyte imbalance  :  changes  in  potassium  or  sodium  levels.

Serious or Rare Side Effects

• Severe hypotension  :  dangerously low blood pressure.
• Acute kidney injury  :  rapid  decline  in  renal  function.
• Hyperkalemia  :  elevated  potassium  levels.
• Angio‑Ang   :  swelling  of  face  or  airway  that  could  threaten  life  if  untreated  .
• Liver dysfunction  :  abnormal  liver  enzyme  tests  or  jaundice.

Patients should be evaluated for renal function, electrolyte status, and cardiovascular health before initiating therapy.

• Monitor blood pressure: ensure target levels are achieved without excessive drop.
• Assess renal function: check creatinine and eGFR periodically.
• Check electrolytes: especially potassium and sodium levels.
• Review concomitant medications: avoid drugs that may cause additive hypotension.
• Pregnancy: contraindicated in the second and third trimesters; discuss risks with a physician.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: concurrent use with ACE inhibitors or other ARBs increases risk of kidney injury and hyperkalemia.
• Potassium‑rich supplements: may cause dangerous hyper‑kalemia.
• Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Loop diuretics: additive diuretic effect may cause volume depletion.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.